RecruitingNCT06459648

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Prediction Study or Response to Treatment With Anti-CGRP Monoclonal Antibodies in Migraine

Sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Enrollment

350 participants

Start Date

Apr 26, 2023

Study Type

OBSERVATIONAL

Conditions

Migraine

Summary

Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Headache record, a drug called Monoclonal antibody anti-CGRP, and others for people with migraine. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHeadache record

The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.

OTHERScales

Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.

DRUGMonoclonal antibody anti-CGRP

Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab